+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms

Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms

Plos One 9(3): E92117

Staphylococcus aureus in its biofilm form has been associated with recalcitrant chronic rhinosinusitis with significant resistance to conventional therapies. This study aims to determine if liposomal-encapsulation of a precursor of the naturally occurring antimicrobial nitric oxide (NO) enhances its desired anti-biofilm effects against S. aureus, in the hope that improving its efficacy can provide an effective topical agent for future clinical use. S. aureus ATCC 25923 biofilms were grown in-vitro using the Minimum Biofilm Eradication Concentration (MBEC) device and exposed to 3 and 60 mg/mL of the NO donor isosorbide mononitrate (ISMN) encapsulated into different anionic liposomal formulations based on particle size (unilamellar ULV, multilamellar MLV) and lipid content (5 and 25 mM) at 24 h and 5 min exposure times. Biofilms were viewed using Live-Dead Baclight stain and confocal scanning laser microscopy and quantified using the software COMSTAT2. At 3 and 60 mg/mL, ISMN-ULV liposomes had comparable and significant anti-biofilm effects compared to untreated control at 24 h exposure (p = 0.012 and 0.02 respectively). ULV blanks also had significant anti-biofilm effects at both 24 h and 5 min exposure (p = 0.02 and 0.047 respectively). At 5 min exposure, 60 mg/mL ISMN-MLV liposomes appeared to have greater anti-biofilm effects compared to pure ISMN or ULV particles. Increasing liposomal lipid content improved the anti-biofilm efficacy of both MLV and ULVs at 5 min exposure. Liposome-encapsulated "nitric oxide" is highly effective in eradicating S. aureus biofilms in-vitro, giving great promise for use in the clinical setting to treat this burdensome infection. Further studies however are needed to assess its safety and efficacy in-vivo before clinical translation is attempted.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 054139882

Download citation: RISBibTeXText

PMID: 24658315

Related references

Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylcoccus aureus by murine macrophages. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology 28(5): 415-428, 2000

Controlled and Localized Nitric Oxide Precursor Delivery From Chitosan Gels to Staphylococcus aureus Biofilms. Journal of Pharmaceutical Sciences 106(12): 3556-3563, 2017

Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis. International Ophthalmology 13(3): 181-185, 1989

Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. Plos One 4(11): E7804, 2010

Efficacies of liposome-encapsulated enrofloxacin against Staphylococcus aureus infection in Anatolian shepherd dog monocytes in vitro. Deutsche Tieraerztliche Wochenschrift 112(6): 219-223, 2005

Competitive Trapping of Nitric Oxide (NO) Between Fe(III)-dithiocarbamate Complex and Liposome-encapsulated Trimethylammonio-PTIO: Effects of Ligand Structure, Charge on Liposome Surface, and External Pressure on NO-trapping Rates. Applied Magnetic Resonance 39(3): 261-272, 2010

A liposome-encapsulated spin trap for the detection of nitric oxide. Free Radical Biology and Medicine 96: 199-210, 2018

Efficacies of free and liposome-encapsulated enrofloxacin (BaytrilReg.) against Staphylococcus aureus infection in Turkish Shepherd Dog neutrophils in vitro. Revue de Medecine Veterinaire 151(5): 415-420, 2000

Antimicrobial efficacy of liposome-encapsulated silver ions and tea tree oil against Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans. 2013

Antimicrobial activity of free and liposome-encapsulated thymol and carvacrol against Salmonella and Staphylococcus aureus adhered to stainless steel. International Journal of Food Microbiology 252: 18-23, 2017

Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Critical Care Medicine 29(1): 1-7, 2001

Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA. Antimicrobial Agents and ChemoTherapy 53(7): 2871-2878, 2009

First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Research 26(4b): 2841-2848, 2006

Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrobial Agents and ChemoTherapy 31(12): 1897-1900, 1987

Cross protection between an encapsulated strain of Staphylococcus hyicus and encapsulated strains of Staphylococcus aureus. Journal of Applied Bacteriology 65(6): 491-499, 1988